Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy
Authors:
- Thompson G. RobinsonTRThompson G. Robinson
- Xia WangXWXia Wang
- Hisatomi ArimaHAHisatomi Arima
- Philip M. BathPBPhilip M. Bath
- Laurent BillotLBLaurent Billot
- Joseph P. BroderickJBJoseph P. Broderick
- Andrew M. DemchukADAndrew M. Demchuk
- Geoffery A. DonnanGDGeoffery A. Donnan
- Jong S. KimJKJong S. Kim
- Pablo M. LavadosPLPablo M. Lavados
- Tsong-Hai LeeTLTsong-Hai Lee
- Richard I. LindleyRLRichard I. Lindley
- 1 July 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (7) , 1877-1883
Abstract
Background and Purpose—: Many patients receiving thrombolysis for acute ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Methods—: Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset, 752 (22.9%) reported prior APT use. Primary outcome at 90 days was the combined end point of death or disability (modified Rankin Scale [mRS] scores, 2–6). Other outcomes included mRS scores 3 to 6, ordinal mRS shift, and symptomatic intracerebral hemorrhage by various standard criteria. Results—: There were no significant differences in outcome between patients with and without prior APT after adjustment for baseline characteristics and management factors during the first week; defined by mRS scores 2 to 6 (adjusted odds ratio [OR], 1.01; 95% confidence interval [CI], 0.81–1.26; P =0.953), 3 to 6 (OR, 0.95; 95% CI, 0.75–1.20; P =0.662), or ordinal mRS shift (OR, 1.03; 95% CI, 0.87–1.21; P =0.770). Alteplase-treated patients on prior APT had higher symptomatic intracerebral hemorrhage (OR, 1.82; 95% CI, 1.00–3.30; P =0.051) according to the safe implementation of thrombolysis in stroke-monitoring study definition. Although not significant ( P -trend, 0.053), low-dose alteplase tended to have better outcomes than standard-dose alteplase in those on prior APT compared with those not using APT (mRS scores of 2–6; OR, 0.84; 95% CI, 0.62–1.12 versus OR, 1.16; 95% CI, 0.99–1.36). Conclusions—: Low-dose alteplase may improve outcomes in thrombolysis-treated acute ischemic stroke patients on prior APT, but this requires further evaluation in a randomized controlled trial. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01422616.Keywords
This publication has 28 references indexed in Scilit:
- Guidelines for the Early Management of Patients With Acute Ischemic StrokeStroke, 2013
- Thrombolysis in Stroke Despite Contraindications or Warnings?Stroke, 2013
- Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trialThe Lancet, 2012
- Current Status of Intravenous Thrombolysis for Acute Ischemic Stroke in AsiaInternational Journal of Stroke, 2011
- Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese PatientsStroke, 2010
- Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy at Stroke OnsetStroke, 2010
- Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled TrialsStroke, 2008
- The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic StrokeStroke, 2008
- Two Tales: Hemorrhagic Transformation but Not Parenchymal Hemorrhage After Thrombolysis Is Related to Severity and Duration of IschemiaStroke, 2007
- Previous Use of Aspirin and Baseline Stroke SeverityStroke, 2006